Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Glaucoma in perspective

- PMLiVE

Rare Disease Day 2025 – highlighting recent approvals in the rare disease space

There are more than 7,000 known rare diseases that impact 300 million people globally

- PMLiVE

Researchers discover previously unidentified genes linked to rare diseases

Up to 80% of rare disease patients remain undiagnosed after genomic sequencing

- PMLiVE

Defying the odds: speeding patient access to life-changing treatments in rare disease

To deliver treatments for rare diseases more quickly, companies share how they are adapting their launch strategies and engaging more deeply with physicians and experts

- PMLiVE

Astrategia

Strategy blindness is a thing

- PMLiVE

Medscape’s Impact on Women’s Health Education: Key Publications at ISSWSH 2025 & Beyond

Just in time for Women’s History Month and International Women’s Day on March 8th, Medscape is proud to showcase its dedication to advancing women's health education. Sara Thorpe, MPH, Director,...

Medscape Education

Embracing Webcams in Virtual Meetings – Building Company Culture Virtually

Tired of the disconnect in virtual meetings? Discover how using webcams can enhance communication, build stronger relationships, and create a more engaging work environment.

Impetus Digital

- PMLiVE

Eli Lilly unveils plans to invest $27bn in four new US manufacturing sites

The investment raises the company’s total US capital expansion commitments to more than $50bn since 2020

EU flag

EC approves Celltrion’s RoActemra biosimilar Avtozma for inflammatory diseases

The drug has been approved for rheumatoid arthritis, giant cell arteritis and other indications

- PMLiVE

Why local knowledge is key to global pharmacovigilance outcomes

The challenge for companies is to ensure their local affiliates meet local PV obligations while staying aligned with global PV requirements

- PMLiVE

Amgen’s Blincyto recommended by NICE for new adult leukaemia indication

Up to 50% of acute lymphoblastic leukaemia patients will relapse after initial treatment

- PMLiVE

AstraZeneca’s camizestrant shows promise in phase 3 breast cancer study

More than two million cases of the disease were diagnosed globally in 2022

- PMLiVE

J&J’s shares positive results for subcutaneous Tremfya in phase 3 ulcerative colitis trial

Inflammatory bowel disease affects almost one in every 100 people in the US

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links